Kuopio, Finland, February 21, 2018 --(PR.com
)-- Experimentica Ltd.
has been selected for Phase 1 of the Young Innovative Company program by Business Finland (formerly known as TEKES, The Finnish Funding Agency for Technology and Innovation). The funding awarded for the first phase is a 250,000 € grant for a period of 12 months.
“Every year, Business Finland selects the most promising and rapidly growing new companies for its Young Innovative Company funding program. The prerequisites and selection criteria include the company’s age, size, ownership, potential for growth, financial stability and a commitment to and track record of innovation on the global market,” said Dr. Giedrius Kalesnykas, CEO of Experimentica Ltd. “We are very thankful for and proud of this recognition. We are confident that the Phase 1 funding will accelerate our unprecedented growth and expansion into novel ophthalmic drug development markets.”
Experimentica Ltd. is a global contract research organization specialized in ocular models. Headquartered in Kuopio, Finland, Experimentica Ltd. focuses on Accelerating Ophthalmic Drug Discovery by offering an industry-leading portfolio for ophthalmic drug development.